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A Supplementary Text

A.1. Detailed derivation of uncertainty propagation analysis.
The probability of sampling x mutant molecules from a well--mixed homogenate into a PCR well can be described using Poisson distribution:
( ) 0,1, , ! 
where λ is the mean number of mutant templates per well. Thus, the probability of sampling zero mutant template into an PCR well, p 0 is simply:
Thus, the unknown parameter λ can be estimated from the fraction of wells that are observed to be un--amplified in a given PCR trial as:
where 0 0 wells p n n = and n 0 and n wells are the number of unamplified and total wells used in the trial, respectively. Since only a small number of n wells is practical, and given that there are but two possible outcomes associated with each PCR wells (either the well is amplified due to the presence of DNA template or the well remains unamplified), the number n 0 follows a Binomial distribution with a probability given by: The uncertainty analysis of ! relies on a first order linear approximation, in which the variance of any function of random variables, ( ) y g x = is approximated from a Taylor Series Expansion (TSE) about the estimator for the mean of the random variables x, given by
where x is an unbiased estimator of the mean of x. Since 0 p is an unbiased estimate for p 0 , the uncertainty in the estimate ! or ( ) V λ can be obtained as a function of the uncertainty in 0 p according to: 
The coefficient of variation (CV) for the above function thus becomes
The CV from the linearized analysis above has a minimum inflection at about 0 0.2 p ≈ , which is in agreement with the Monte Carlo simulations below ( Supplementary Fig. 1A and Figure. 2A in the main text).
The mutation frequency estimate θ (mutant per base pair) can then be calculated from ! according to: b
where n mtDNA is the total number of mtDNA in a single PCR well and n bp is the length DNA template in consideration (in base pairs; e.g., n bp = 4 for TaqI recognition site (7) 
A.3. Simulation Methodology
Following our mtDNA point mutation model (26) , the in silico model developed in this work, tracks for mtDNA mutation accumulation during two stages: developmental and postnatal ( Figure   TXT1 ). The model comprises of tracking the wild--type mtDNA (W) and mtDNA deletion (M) in each cardiomyocytes of the mouse heart tissue ( 6 25 10 × cells). Each mutant mtDNA molecule is assumed to contain only a single mutation in the TaqI recognition site (TCGA), consistent with the RMC experimental design (7). The probability of finding two or more mutations at the same site is negligible (3). In the subsequent section, details of the stochastic model used in this work for the CME representation of mitochondrial turnover process will be discussed. 
A.3.1. Cell--level modeling details
Based on experimental evidence, each mitochondrion is assumed to contain 10 mtDNA organized into assemblies called nucleoids (28, 29) . The model simulates two mtDNA--related maintenance processes: mitochondrial turnover comprising of relaxed replication and degradation of mtDNA, and de novo point mutations arising during mtDNA replication ( Figure  TXT2 ). The model is based on a minimal conservative assumption of the cellular mtDNA population existing as a well--mixed pool, due to fast fusion and fission dynamics of mitochondria (30) . Analysis of mtDNA replication process using labeling kinetics have indicated that all genome replicate independent from each other and also the independence is conserved at the level of nucleoids (28) . Consistent with these observations, in a turnover event, each mitochondrial DNA is randomly sampled and subjected to replication. Each mitochondrion that undergoes autophagy (or mitophagy) is assumed to contain random number of mtDNA copy number ( mito n ), sampled according to Poisson distribution (with mean mtDNA count = 10) (27, 28) , and the number of wild--type mtDNA undergoing degradation is obtained as:
where x represents the number of wild type mtDNA chosen for the mitophagy.
De novo point mutation can occur during replication of mtDNA due to mis--pairing associated with ROS--induced mutagenic lesions such as 8--hydroxy--2--deoxyguanosine (8OHdG) (31) or as random errors arising due to finite polymerase--γ (POLG) fidelity (32) . Consequently, each replication of a wild--type mtDNA has a finite probability, given by the mutation rate constant (k m ), to produce a mutant. In a mutation event, single mutated mtDNA forms and the original mtDNA molecule remains intact. Thus, in the event of a de novo point mutation, mutant mtDNA count is increased and the wild--type mtDNA population is conserved. Here, the number of de novo mutant mtDNA is randomly chosen from a binomial distribution: (27) ( )
where y denotes the number of de novo mutations resulting from replication of x wild--type mtDNA. Based on these probabilities, the in silico model is formulated as Chemical Master Equation (CME) (33) in which each mtDNA--related process: replication without mutation, replication with de novo mutations and degradation, is described as a jump Markov process with the following state transitions ( Figure TXT2 ):
The first two transitions reflect the mitochondrial degradation (mitophagy), the third and forth reactions represent replication of mtDNA without mutation, and the last reaction represents the de novo mtDNA point mutation. A general formulation of CME for the mtDNA turnover process is given by (26, 34) : 
The probability density function ( ) 2. Based on the propensities, generate random samples of (τ , j) as in the SSA algorithm (33, 35) .
3. Select ten mtDNA molecules randomly from the population (hypergeometric sampling) for mitochondrial degradation and similarly select a single mtDNA from the population for the process of replication. Each replication of a wild type mtDNA can result in a mutant mtDNA with a probability given by the mutation rate constant ( m k ).
4. Update W and M based on events in steps 2 and 3 and increment the time t byτ .
Repeat steps 1 through 4 until the desired end time.
To predict mtDNA mutation burden in a single organ or tissue, millions of such simulations are performed to capture the mtDNA dynamics of all cells in a tissue.
A.3.2. Tissue--level modeling details
A.3.2.1. Simulations of mouse development
The developmental simulation not only captures the rapid increase in cell number and the associated increase in the mtDNA copy number in the developmental embryonic cells, but also accounts for the normal turnover of mtDNA. The embryonic cell divisions begin after fertilization of an oocyte. Mouse oocytes harbor a large number of mitochondria (~1.5×10 5 mtDNA) (36) , which allow the zygote to multiply initially without the need to replicate mtDNA (37, 38) . (Table  TXT1 ). The segregation of wild--type and mutant mtDNA between the daughter cells is assumed to occur at random, without any selective advantage according to a hypergeometric distribution: (27)
where x denotes the number of wild--type mtDNA in one of the daughter cells after segregation and n is the total number of mtDNA in a single daughter cell (i.e., n = (W+M)/2). During development, POLG the care taker of the mtDNA replication fidelity, is the main contributor for point mutations in mtDNA, with negligible oxidative activity and damage (32, 44) .
A.3.2.2. Simulations of postnatal stage
After birth, cardiomyocytes do not undergo further cellular division. However, the mtDNA population in cardiomyocytes undergoes hypertrophic growth. The mtDNA population in the mouse cardiomyocytes increases from 1000 molecules to ~3500 copies per cell (45--47) . After reaching the nominal count of mtDNA in adult cardiomyocytes (47) , the mtDNA copy number of cardiomyocytes is held at constant level, by relaxed replication (48) . The functional significance of relaxed replication in postmitotic tissues like heart and brain is to maintain a healthy population of mtDNA to satisfy the cellular energy requirements (48, 49) . The postmitotic simulations continue from cells produced at the last stage of development ( Figure  TXT1 ), in which each cell maintains mitochondrial biogenesis to balance degradation. Like the developmental stage, the POLG replication fidelity is assumed to be the main contributor for point mutations in mtDNA, with negligible oxidative activity and damage.
A.3.2.3. Calculation of mtDNA point mutation frequency
The point mutation burden (mutation frequency) per base pair is determined using,
where W tot and M tot are the total number of wild--type and mutant mtDNA molecules in the tissue, respectively. Consistent with the original work, the length of TaqI recognition site used in the RMC assay is 4 bp (7) . Note, that the probability of a molecule with two or more mutations in the same TaqI site is negligible (7).
All simulations were performed using an IBM high performance computing cluster with 140 Intel 1.6 GHz processors. The simulations were coded and compiled using GNU C++ compiler; G++ (v4.1.1) and run on CentOS (RHEL) Linux platform. On average a complete simulation of a heart tissue (~20 million cells) from the development to the end of 3 years of mouse's life span required approximately 7 hours.
A.3.3. Model Parameters
Model parameters are compiled from published data for mice and we have ensured that they are The mtDNA copy number is maintained throughout the cell growth and divisions (51) . The mtDNA replication should occur to balance the degradation. We have used a constant biogenesis model to simulate the mtDNA replication process. The constant mtDNA replication rate was deduced based on the homeostatic mtDNA copy number in a cell and the degradation rate of mtDNA.
Thus, the replication constant k R is given by:
A.3.3.3. Mitochondrial DNA point mutation rate (k m )
The fidelity of polymerase--γ contributes to de novo point mutations during replication. The polymerase is responsible for the replication and proof reading of newly synthesized strands with a reported error rate between 1×10 --7 and 1×10 --6 bp --1 replication --1 for the wild--type enzyme (32) . A conservative value (lowest) of 1×10 --7 bp --1 replication --1 is chosen for wild--type mouse simulations.
All the other model parameters are consistent with our earlier work (26) and the model parameters are compiled from the published data on mice and we have ensured to select parameters that are consistent with the current literature and the state of the art measurement techniques. The summary of all the parameters used in this work is described in Table TXT1 . Supplementary Table 1 : Frequencies of false positives and false negatives encountered during the RMC trials. Data is based on the quality control experiments of the RMC assay conducted using the NTC's and mtDNA templates. Trials used for obtaining the false positive error frequencies were conducted with PCR amplification of the wells having pure buffer (NTC's). Whereas, the trails used for determining the false negative error frequencies were based on amplification of the PCR wells with an average of 10 mtDNA templates in each of the PCR wells. 
C. SUPPLEMENTARY TABLES
